Selective and Brain‐Permeable Polo‐like Kinase‐2 (Plk‐2) Inhibitors That Reduce α‐Synuclein Phosphorylation in Rat Brain

Polo‐like kinase‐2 (Plk‐2) has been implicated as the dominant kinase involved in the phosphorylation of α‐synuclein in Lewy bodies, which are one of the hallmarks of Parkinson’s disease neuropathology. Potent, selective, brain‐penetrant inhibitors of Plk‐2 were obtained from a structure‐guided drug discovery approach driven by the first reported Plk‐2–inhibitor complexes. The best of these compounds showed excellent isoform and kinome‐wide selectivity, with physicochemical properties sufficient to interrogate the role of Plk‐2 inhibition in vivo. One such compound significantly decreased phosphorylation of α‐synuclein in rat brain upon oral administration and represents a useful probe for future studies of this therapeutic avenue toward the potential treatment of Parkinson’s disease.

[1]  A. Cheng,et al.  Structure of the catalytic domain of human polo-like kinase 1. , 2007, Biochemistry.

[2]  W. Dai,et al.  Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions. , 2008, Cancer research.

[3]  E. Masliah,et al.  Phosphorylation of Synucleins by Members of the Polo-like Kinase Family* , 2009, The Journal of Biological Chemistry.

[4]  Matthew M. Davis,et al.  (3R,7aS)-3-(TRICHLOROMETHYL)TETRAHYDROPYRROLO[1,2-C]OXAZOL-1(3H)-ONE: AN AIR AND MOISTURE STABLE REAGENT FOR THE SYNTHESIS OF OPTICALLY ACTIVE α-BRANCHED PROLINES. , 2009, Organic syntheses; an annual publication of satisfactory methods for the preparation of organic chemicals.

[5]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[6]  Hideo Fujiwara,et al.  Hyperphosphorylation and insolubility of α‐synuclein in transgenic mouse oligodendrocytes , 2002 .

[7]  Anders Björklund,et al.  Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors , 2003, Trends in Neurosciences.

[8]  S. V. Ley,et al.  Moderne Synthesemethoden: Kupfer-vermittelte C(Aryl)-O-, C(Aryl)-N- und C(Aryl)-S-Verknüpfungen , 2003 .

[9]  Péter Lénárt,et al.  BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo , 2007, Current Biology.

[10]  M. Sheng,et al.  Critical Role of CDK5 and Polo-like Kinase 2 in Homeostatic Synaptic Plasticity during Elevated Activity , 2008, Neuron.

[11]  S. Ley,et al.  Modern Synthetic Methods for Copper‐Mediated C(aryl) ? O, C(aryl) ? N, and C(aryl) ? S Bond Formation , 2003 .

[12]  T. Iwatsubo,et al.  Phosphorylation of α-synuclein characteristic of synucleinopathy lesions is recapitulated in α-synuclein transgenic Drosophila , 2003, Neuroscience Letters.

[13]  F. Féru,et al.  Research Article: Selectivity‐determining Residues in Plk1 , 2007, Chemical biology & drug design.

[14]  R. Barbour,et al.  Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.

[15]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[16]  M. A. Carrondo,et al.  Structure of wild-type Plk-1 kinase domain in complex with a selective DARPin. , 2008, Acta crystallographica. Section D, Biological crystallography.

[17]  I. Gallou,et al.  Expedient synthesis of substituted imidazoles from nitriles , 2005 .

[18]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[19]  R. Medema,et al.  Polo-Like Kinases: A Team in Control of the Division , 2006, Cell cycle.

[20]  Ikuko Fujiwara,et al.  Microscopic analysis of polymerization dynamics with individual actin filaments , 2002, Nature Cell Biology.

[21]  J. Malone,et al.  Attractive intramolecular edge-to-face aromatic interactions in flexible organic molecules. , 2001, Accounts of chemical research.

[22]  J. Charron,et al.  Role of Plk2 (Snk) in Mouse Development and Cell Proliferation , 2003, Molecular and Cellular Biology.

[23]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[24]  M. Chesselet,et al.  In vivo alpha-synuclein overexpression in rodents: A useful model of Parkinson's disease? , 2008, Experimental Neurology.

[25]  Normand L. Frigon,et al.  Polo-like Kinase 2 (PLK2) Phosphorylates α-Synuclein at Serine 129 in Central Nervous System*S⃞ , 2009, Journal of Biological Chemistry.

[26]  C. Bouras,et al.  Neuropathology of Lewy body disorders , 2009, Brain Research Bulletin.

[27]  A. Ullrich,et al.  Targeting polo-like kinase 1 for cancer therapy , 2006, Nature Reviews Cancer.

[28]  Hideo Fujiwara,et al.  Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. , 2002, The Journal of clinical investigation.

[29]  Ming Fan,et al.  Involvement of the Snk-SPAR pathway in glutamate-induced excitotoxicity in cultured hippocampal neurons , 2007, Brain Research.

[30]  U. Staubli,et al.  The polo‐like protein kinases Fnk and Snk associate with a Ca2+‐ and integrin‐binding protein and are regulated dynamically with synaptic plasticity , 1999, The EMBO journal.

[31]  T. Iwatsubo,et al.  Accumulation of Phosphorylated α‐Synuclein in Aging Human Brain , 2003 .

[32]  P. Kollman,et al.  Continuum Solvent Studies of the Stability of DNA, RNA, and Phosphoramidate−DNA Helices , 1998 .

[33]  H. Sham,et al.  A facile synthesis of multigram quantity of ethyl 3-ethylmorpholine-3-carboxylate , 2011 .

[34]  R. Weissleder,et al.  Bioorthogonal probes for polo-like kinase 1 imaging and quantification. , 2011, Angewandte Chemie.

[35]  M. Leung,et al.  An improved Ullmann–Ukita–Buchwald–Li conditions for CuI-catalyzed coupling reaction of 2-pyridones with aryl halides , 2005 .

[36]  Jay A. Tischfield,et al.  The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus , 2010, Nucleic acids research.

[37]  V. Baekelandt,et al.  Kinases as targets for Parkinson's disease: from genetics to therapy. , 2011, CNS & neurological disorders drug targets.

[38]  M. Voss,et al.  A simple and convenient one-pot method for the preparation of heteroaryl-2-imidazoles from nitriles , 2008 .

[39]  P. Beroza,et al.  Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors. , 2013, Bioorganic & medicinal chemistry letters.

[40]  Philip L De Jager,et al.  Parkinson's disease: genetics and pathogenesis. , 2011, Annual review of pathology.

[41]  T. Burns,et al.  Silencing of the Novel p53 Target Gene Snk/Plk2 Leads to Mitotic Catastrophe in Paclitaxel (Taxol)-Exposed Cells , 2003, Molecular and Cellular Biology.

[42]  H. Sham,et al.  Design, synthesis, and structure-activity relationship of novel orally efficacious pyrazole/sulfonamide based dihydroquinoline gamma-secretase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[43]  J. Isaac,et al.  Plk2 attachment to NSF induces homeostatic removal of GluA2 during chronic overexcitation , 2010, Nature Neuroscience.

[44]  Jan Hermans,et al.  Discrimination between native and intentionally misfolded conformations of proteins: ES/IS, a new method for calculating conformational free energy that uses both dynamics simulations with an explicit solvent and an implicit solvent continuum model , 1998, Proteins.

[45]  Valérie Gailus-Durner,et al.  Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells , 2011, Nature communications.

[46]  Wenzhe Ma,et al.  Polo-like kinases mediate cell survival in mitochondrial dysfunction , 2009, Proceedings of the National Academy of Sciences.

[47]  Eric F. Johnson,et al.  Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity. , 2007, Biochemistry.

[48]  P. Kollman,et al.  Automatic atom type and bond type perception in molecular mechanical calculations. , 2006, Journal of molecular graphics & modelling.

[49]  M. Sheng,et al.  Targeted Protein Degradation and Synapse Remodeling by an Inducible Protein Kinase , 2003, Science.

[50]  David M. Glover,et al.  Polo-like kinases: conservation and divergence in their functions and regulation , 2009, Nature Reviews Molecular Cell Biology.

[51]  U. Hoffmann‐Rohrer,et al.  Polo-like Kinase-2 Is Required for Centriole Duplication in Mammalian Cells , 2004, Current Biology.

[52]  K. Strebhardt,et al.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy , 2010, Nature Reviews Drug Discovery.

[53]  Bhyravabhotla Jayaram,et al.  Free Energy Analysis of the Conformational Preferences of A and B Forms of DNA in Solution , 1998 .